CL2015001391A1 - Compuestos derivados de hidantoina, análogo de pth; composicion farmaceutica; metodo para la prevencion o el tratamieno de osteoporosis,fracturas, hipocondroplasia; y su uso para la produccion de un agente movilizador de celulas madre o un agente para prevenir o tratar osteoporosis, entre otras - Google Patents

Compuestos derivados de hidantoina, análogo de pth; composicion farmaceutica; metodo para la prevencion o el tratamieno de osteoporosis,fracturas, hipocondroplasia; y su uso para la produccion de un agente movilizador de celulas madre o un agente para prevenir o tratar osteoporosis, entre otras

Info

Publication number
CL2015001391A1
CL2015001391A1 CL2015001391A CL2015001391A CL2015001391A1 CL 2015001391 A1 CL2015001391 A1 CL 2015001391A1 CL 2015001391 A CL2015001391 A CL 2015001391A CL 2015001391 A CL2015001391 A CL 2015001391A CL 2015001391 A1 CL2015001391 A1 CL 2015001391A1
Authority
CL
Chile
Prior art keywords
osteoporosis
agent
hypochondroplasia
hydantoin
fractures
Prior art date
Application number
CL2015001391A
Other languages
English (en)
Inventor
Yoshikazu Nishimura
Toru Esaki
Tatsuya Tamura
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CL2015001391A1 publication Critical patent/CL2015001391A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2015001391A 2012-12-10 2015-05-22 Compuestos derivados de hidantoina, análogo de pth; composicion farmaceutica; metodo para la prevencion o el tratamieno de osteoporosis,fracturas, hipocondroplasia; y su uso para la produccion de un agente movilizador de celulas madre o un agente para prevenir o tratar osteoporosis, entre otras CL2015001391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012269178 2012-12-10

Publications (1)

Publication Number Publication Date
CL2015001391A1 true CL2015001391A1 (es) 2015-07-31

Family

ID=50934349

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015001391A CL2015001391A1 (es) 2012-12-10 2015-05-22 Compuestos derivados de hidantoina, análogo de pth; composicion farmaceutica; metodo para la prevencion o el tratamieno de osteoporosis,fracturas, hipocondroplasia; y su uso para la produccion de un agente movilizador de celulas madre o un agente para prevenir o tratar osteoporosis, entre otras
CL2017000069A CL2017000069A1 (es) 2012-12-10 2017-01-11 Derivado de hidantoina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2017000069A CL2017000069A1 (es) 2012-12-10 2017-01-11 Derivado de hidantoina.

Country Status (35)

Country Link
US (5) US9428505B2 (es)
EP (1) EP2930176B1 (es)
JP (1) JP5951799B2 (es)
KR (1) KR102168738B1 (es)
CN (1) CN104854106B (es)
AU (1) AU2013358167B2 (es)
BR (1) BR112015012411B1 (es)
CA (1) CA2892621C (es)
CL (2) CL2015001391A1 (es)
CR (1) CR20150272A (es)
DK (1) DK2930176T3 (es)
ES (1) ES2663797T3 (es)
HK (1) HK1209735A1 (es)
HR (1) HRP20180647T1 (es)
HU (1) HUE037530T2 (es)
IL (1) IL238277B (es)
LT (1) LT2930176T (es)
MA (1) MA38250B1 (es)
MX (1) MX2015007309A (es)
MY (1) MY178583A (es)
NO (1) NO2930176T3 (es)
NZ (1) NZ707946A (es)
PE (1) PE20151295A1 (es)
PH (1) PH12015501146A1 (es)
PL (1) PL2930176T3 (es)
PT (1) PT2930176T (es)
RS (1) RS57190B1 (es)
RU (1) RU2678984C2 (es)
SA (1) SA515360528B1 (es)
SG (1) SG11201504204XA (es)
SI (1) SI2930176T1 (es)
TW (1) TWI615394B (es)
UA (1) UA115072C2 (es)
WO (1) WO2014092061A1 (es)
ZA (1) ZA201503597B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433940B9 (en) 2009-04-28 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
TWI615394B (zh) * 2012-12-10 2018-02-21 Chugai Pharmaceutical Co Ltd 乙內醯脲衍生物
EP3153166B1 (en) * 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition
US20210290541A1 (en) * 2018-07-30 2021-09-23 Chugai Seiyaku Kabushiki Kaisha Solid dispersion of hydantoin derivative
CN110464002A (zh) * 2019-09-12 2019-11-19 西南石油大学 一种天然冰粉的制备方法及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) * 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
EP1137640B1 (en) 1998-12-11 2005-09-21 F. Hoffmann-La Roche Ag Cyclic hydrazine derivatives as tnf-alpha inhibitors
EP1321141A4 (en) 2000-08-30 2004-02-18 Teijin Ltd INHIBITORS OF PARATHORMONE PRODUCTION CONTAINING VITAMIN D3 DERIVATIVES
SK4972003A3 (en) * 2000-10-26 2004-05-04 Pfizer Prod Inc 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
EP1514246A4 (en) * 2002-06-06 2008-04-16 Donnelly Corp COMPASS INTERIOR COURTESY MIRROR SYSTEM
US20070099940A1 (en) * 2004-02-11 2007-05-03 Spearing Paul K Pth agonists
WO2005077918A1 (en) * 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
US7659264B2 (en) 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
JP2009541342A (ja) 2006-06-20 2009-11-26 ワイス Ｋｖ１．５カリウムチャネル阻害剤
WO2008148689A1 (en) 2007-06-07 2008-12-11 F. Hoffmann-La Roche Ag Prolinamide derivatives as nk3 antagonists
CA2707857C (en) 2007-12-10 2016-09-13 Novartis Ag Spirocyclic amiloride analogues
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8513193B2 (en) 2008-10-13 2013-08-20 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
EP2433940B9 (en) * 2009-04-28 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Spiroimidazolone derivative
TWI615394B (zh) * 2012-12-10 2018-02-21 Chugai Pharmaceutical Co Ltd 乙內醯脲衍生物
EP3153166B1 (en) * 2014-06-09 2022-08-03 Chugai Seiyaku Kabushiki Kaisha Hydantoin derivative-containing pharmaceutical composition

Also Published As

Publication number Publication date
PH12015501146B1 (en) 2015-08-10
US20150274727A1 (en) 2015-10-01
IL238277A0 (en) 2015-06-30
HRP20180647T1 (hr) 2018-06-01
US20220162208A1 (en) 2022-05-26
IL238277B (en) 2018-01-31
US20160326175A1 (en) 2016-11-10
JP5951799B2 (ja) 2016-07-13
AU2013358167A1 (en) 2015-04-09
EP2930176A4 (en) 2016-06-01
US20210024524A1 (en) 2021-01-28
LT2930176T (lt) 2018-04-10
CA2892621C (en) 2021-02-16
DK2930176T3 (en) 2018-03-19
MX2015007309A (es) 2015-09-10
NZ707946A (en) 2019-11-29
EP2930176A1 (en) 2015-10-14
RU2678984C2 (ru) 2019-02-05
NO2930176T3 (es) 2018-07-07
EP2930176B1 (en) 2018-02-07
PL2930176T3 (pl) 2018-07-31
TWI615394B (zh) 2018-02-21
MA38250A1 (fr) 2017-02-28
CA2892621A1 (en) 2014-06-19
AU2013358167B2 (en) 2017-09-14
CR20150272A (es) 2015-07-09
HK1209735A1 (en) 2016-04-08
WO2014092061A1 (ja) 2014-06-19
CN104854106A (zh) 2015-08-19
US9428505B2 (en) 2016-08-30
CN104854106B (zh) 2017-07-04
HUE037530T2 (hu) 2018-09-28
PT2930176T (pt) 2018-04-03
RS57190B1 (sr) 2018-07-31
JPWO2014092061A1 (ja) 2017-01-12
SA515360528B1 (ar) 2018-05-24
BR112015012411A2 (pt) 2017-07-11
UA115072C2 (uk) 2017-09-11
ES2663797T3 (es) 2018-04-17
SG11201504204XA (en) 2015-07-30
US20180237436A1 (en) 2018-08-23
SI2930176T1 (en) 2018-06-29
KR102168738B1 (ko) 2020-10-22
BR112015012411B1 (pt) 2021-10-05
PE20151295A1 (es) 2015-10-10
RU2015127624A (ru) 2017-01-16
CL2017000069A1 (es) 2017-08-25
ZA201503597B (en) 2016-09-28
PH12015501146A1 (en) 2015-08-10
TW201439092A (zh) 2014-10-16
KR20150092275A (ko) 2015-08-12
MA38250B1 (fr) 2017-10-31
MY178583A (en) 2020-10-16

Similar Documents

Publication Publication Date Title
CL2015001442A1 (es) Metodo para tratar enfermedades pulmonares que comprende el uso de compuestos derivados del acido obeticolico.
CO6801706A2 (es) Método para inhibir o controlar la liberación del agente de tratamiento de pozo
CL2014003388A1 (es) Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2015001391A1 (es) Compuestos derivados de hidantoina, análogo de pth; composicion farmaceutica; metodo para la prevencion o el tratamieno de osteoporosis,fracturas, hipocondroplasia; y su uso para la produccion de un agente movilizador de celulas madre o un agente para prevenir o tratar osteoporosis, entre otras
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112014029674A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença, utilização de um composto, conjunto para o tratamento de uma condição mediada pela quinase pim e invenção
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112014003681A8 (pt) composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições
CO6551749A2 (es) Dispositivo y método para la aplicción tópica de composiciones terapéuticas o cosméticas
BR112014010179A8 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BR112014007649A2 (pt) material estruturante, e, método para o tratamento de uma formação subterrânea
BR112014005235A2 (pt) composto heterocíclico, composição farmacêutica, agente profilático e/ou terapêutico, e, método para prevenir e/ou tratar uma doença neurológica central
BR112013004456A2 (pt) composição para tratamento de planta, e, método para o tratamento de plantas
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
EP2851071A4 (en) USE OF KAEMPFERIA PARVIFLORA WALL. EX. BACER EXTRACTS OR FLAVOR COMPOUNDS FOR PREVENTING OR TREATING MUSCLE DISEASES OR FOR IMPROVING MUSCLE FUNCTION
BR112012029606A2 (pt) formulação, método para a fabricação de uma fomulação, método de tratamento de uma planta e uso de uma formulação
PL2589579T3 (pl) Zastosowanie zestawu do obróbki powierzchni zaszpachlowanych gipsem, zatartych gipsem lub otynkowanych gipsem
CL2014000172A1 (es) Composicion en spray que comprende a) un portador de oxigeno, tal como hemoglobina o mioglobina; y b) al menos un ingrediente adicional; metodo para preparar la composicion; proceso para purificar un portador de oxigeno; y su uso para el tratamiento externo de heridas.
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
BR112015002493A2 (pt) composto , composição farmacêutica , método para o tratamento do câncer , processo para a preparação de uma composição farmacêutica , conjunto , utilização de um composto e invenção.